Hormone therapyFDA-approvedFirst-line
Darolutamide
How it works
Blocks the action of testosterone on prostate cancer cells, preventing them from growing.
Cancer types
Prostate Cancer— All patients
Efficacy
Darolutamide has been shown to significantly improve metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Darolutamide with Surgery for High-Risk Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Comparing Darolutamide with Androgen Deprivation Therapy in Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Testosterone and Darolutamide for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Studying Darolutamide Safety in Korean Men with Prostate Cancer | Prostate Cancer | preclinical | — | Source → |
| Darolutamide's Benefit in Prostate Cancer Treatment | Prostate Cancer | phase-3 | In the Japanese subgroup, the probability that the darolutamide triplet provided greater utility was 0.601 when considering three criteria, and 0.975 when considering four criteria, including time to castration-resistant prostate cancer. | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Darolutamide and Hormone Therapy for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) compared with darolutamide + ADT. | Source → |
| Darolutamide Improves Prostate Cancer Treatment for Black Patients | Prostate Cancer | observational | Darolutamide + ADT resulted in an additional 1.04 (95% uncertainty interval 0.56-1.51) QALYs per treated patient relative to ADT, with the greatest gain observed among NH-Black patients (1.48 [0.48-2.71]). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.